Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins
Third quarter
- Sales of
SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK.
- Sales per region, in local currencies was +9% in EMEA, +2% in
Americas and +9% in APAC.
- Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics.
- Gross margin increased to 58.6% (55.7).
- Operating income before depreciation and amortisation (EBITDA) was
SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9).
- Operating cash flow decreased to
SEK 206 million (214).
- Net income was
SEK 116 (122) million, resulting in earnings per share ofSEK 0.85 (0.90).
First nine months
- Sales of
SEK 2,650 (2,607) million, an increase of 4% in local currencies and 2% in SEK.
- Sales per region, in local currencies was +6% in EMEA, -2% in
Americas and +7% in APAC.
- Sales per business area, in local currencies was +10% in Consumables, +20% in Technologies and -7% in Genetics.
- Gross margin increased to 58.6% (56.1).
- Operating income before depreciation and amortisation (EBITDA) increased to
SEK 888 (842) million, giving an EBITDA margin of 33.5% (32.3).
- Operating cash flow increased to
SEK 640 million (586).
- Net income was
SEK 375 (328) million, resulting in earnings per share ofSEK 2.76 (2.42).
The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024
Contact:
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Interim report Q3, 2024 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q3-2024-improved-growth-with-solid-margins-302285557.html
SOURCE
